Case number 2016-1962
Otsuka Pharmaceutical Co. v. Zydus Pharmaceuticals USA > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| Apr 23, 2021 | 0 | OTSUKA PHARMACEUTICAL CO. v. ZYDUS PHARMACEUTICALS USA [RULE 36 JUDGMENT] [nonprecedential] (0) |
| Sep 29, 2017 | 170 | Mandate issued to the United States District Court for the District of New Jersey. Service as of this date by Clerk of Court. [464296] [16-1962, 16-1963, 16-1964, 16-1966, 16-1968, 16-1970, 16-1971, 16-1972, 16-1974, 16-1975, 16-1978] [JAB] [Entered: 09/29/2017 10:21 AM] (1) |
| Sep 22, 2017 | 169 | ORDER filed denying [162] petition for panel rehearing filed by Otsuka Pharmaceutical Co., Ltd.; denying [162] petition for en banc rehearing filed by Otsuka Pharmaceutical Co., Ltd. By: En Banc (Per Curiam). Service as of this date by Clerk of Court. [462943] [SJ] [Entered: 09/22/2017 10:58 AM] (3) |
| Sep 20, 2017 | 168 | ORDER filed granting motion to withdraw party [166] filed by Appellees Torrent Pharmaceuticals Limited, Torrent Pharma Inc. and Appellant Otsuka Pharmaceutical Co., Ltd. By: (Per Curiam). Service as of this date by Clerk of Court. [462292] [16-1962, 16-1964] [SJ] [Entered: 09/20/2017 10:12 AM] (2) |
| Sep 14, 2017 | 167 | ORDER filed granting motion to terminate cross/consolidated appeal [164] filed by Appellant Otsuka Pharmaceutical Co., Ltd. and Appellee Alembic Pharmaceuticals Limited; granting motion to withdraw party [165] filed by Appellees Accord Healthcare, Inc., Intas Pharmaceuticals Limited and Appellant Otsuka Pharmaceutical Co., Ltd. By: (Per Curiam). Service as of this date by Clerk of Court. [461101] [16-1962, 16-1968, 16-1973] [SJ] [Entered: 09/14/2017 04:40 PM] (2) |
| Sep 13, 2017 | 166 | MOTION of Appellant Otsuka Pharmaceutical Co., Ltd. and Appellees Torrent Pharma Inc. and Torrent Pharmaceuticals Limited to withdraw party, Torrent Pharmaceuticals Limited and Torrent Pharma Inc., as a party to this appeal. Any response is due within 10 days of service [Consent: unopposed]. Service: 09/13/2017 by email. [460827] [James Monroe] [Entered: 09/13/2017 05:23 PM] (6) |
| Sep 11, 2017 | 165 | MOTION of Appellant Otsuka Pharmaceutical Co., Ltd. and Appellees Accord Healthcare, Inc. and Intas Pharmaceuticals Limited to withdraw party, Accord Healthcare, Inc. and IntasPharmaceuticals Limited, as a party to this appeal. Any response is due within 10 days of service [Consent: unopposed]. Service: 09/11/2017 by email. [460048] [James Monroe] [Entered: 09/11/2017 11:08 AM] (6) |
| Sep 7, 2017 | 164 | MOTION of Appellant Otsuka Pharmaceutical Co., Ltd. and Appellee Alembic Pharmaceuticals Limited to terminate cross/consolidated appeal. Any response is due within 10 days of service [Consent: unopposed]. Service: 09/07/2017 by email. [459546] [James Monroe] [Entered: 09/07/2017 08:47 PM] (6) |
| Aug 23, 2017 | 163 | 18 paper copies of the petition for panel rehearing [162], petition for en banc rehearing [162] received from Appellant Otsuka Pharmaceutical Co., Ltd.. [456098] [SJ] [Entered: 08/23/2017 12:56 PM] (0) |
| Aug 21, 2017 | 162 | Petition for panel rehearing, for en banc rehearing filed by Appellant Otsuka Pharmaceutical Co., Ltd.. Service: 08/21/2017 by email. The paper copies of the petition must be filed within two business days (see Fed. Cir. R. 35(c)(4).The required paper copies should be received by the court on or before 08/23/2017 [455579] [Paul Browning] [Entered: 08/21/2017 07:08 PM] (28) |
| Jul 20, 2017 | 161 | OPINION and JUDGMENT filed. The judgment or decision is: Affirmed. (FCR 36). (For the Court: Prost,Chief Judge; Chen,Circuit Judge and Hughes,Circuit Judge). [447844] [16-1962, 16-1963, 16-1964, 16-1966, 16-1968, 16-1970, 16-1971, 16-1972, 16-1973, 16-1974, 16-1975, 16-1978] [JAB] [Entered: 07/20/2017 10:13 AM] (7) |
| Jul 13, 2017 | 160 | ORDER filed granting motion to terminate consolidated appeal [159] filed by Appellant Otsuka Pharmaceutical Co., Ltd. and Appellees Hetero Drugs Limited, Hetero Labs Limited and Hetero USA, Inc. in 16-1962; issuing mandate in 16-1977. By: Merits Panel (Per Curiam). Service as of this date by Clerk of Court. [446092] [16-1962, 16-1977] [SJ] [Entered: 07/13/2017 09:09 AM] (3) |
| Jul 11, 2017 | 159 | MOTION of Appellant Otsuka Pharmaceutical Co., Ltd. and Appellees Hetero Drugs Limited, Hetero Labs Limited and Hetero USA, Inc. to terminate cross/consolidated appeal. Any response is due within 10 days of service [Consent: unopposed]. Service: 07/11/2017 by email. [445500] [James Monroe] [Entered: 07/11/2017 09:53 AM] (6) |
| Jul 10, 2017 | 157 | Submitted after ORAL ARGUMENT by Paul William Browning for Otsuka Pharmaceutical Co., Ltd. and Lawrence M. Sung for Accord Healthcare, Inc., Ajanta Pharma Limited, Ajanta Pharma USA Inc., Alembic Pharmaceuticals Limited, Amneal Pharmaceuticals India Pvt. Ltd., Amneal Pharmaceuticals, LLC, Apotex Corp., Apotex Inc., Aurobindo Pharma Ltd., Aurobindo Pharma USA Inc., Aurolife Pharma LLC, Cadila Healthcare, Limited, Hetero Drugs Limited, Hetero Labs Limited, Hetero USA, Inc., Intas Pharmaceuticals Limited, Lupin Atlantis Holdings S.A., Lupin Limited, Lupin Pharmaceuticals, Inc., Mylan Inc., Mylan Pharmaceuticals Inc., Torrent Pharma Inc., Torrent Pharmaceuticals Limited and Zydus Pharmaceuticals USA, Inc. Panel: Judge: Prost , Judge: Chen , Judge: Hughes. [445130] [JAB] [Entered: 07/10/2017 11:00 AM] (0) |
| Jul 10, 2017 | 158 | ORDER filed granting motion to withdraw party [154] filed by Appellees Apotex Inc., Apotex Corp. and Appellant Otsuka Pharmaceutical Co., Ltd. in 16-1962. By: Merits Panel (Per Curiam). Service as of this date by Clerk of Court. [445244] [16-1962, 16-1974] [SJ] [Entered: 07/10/2017 02:15 PM] (2) |
| Jul 5, 2017 | 156 | CORRECTED Response to oral argument order from the Appellant Otsuka Pharmaceutical Co., Ltd.. designating Paul W. Browning as arguing attorney. Designated time for argument: 10 minutes. Designated time for rebuttal: 5 minutes. Service of other counsel by Notice of Docket Activity from this entry. [444211] [James Monroe] [Entered: 07/05/2017 02:16 PM] (0) |
| Jul 3, 2017 | 155 | CORRECTED Response to oral argument order from the Appellees Accord Healthcare, Inc., Ajanta Pharma Limited, Ajanta Pharma USA Inc., Alembic Pharmaceuticals Limited, Amneal Pharmaceuticals India Pvt. Ltd., Amneal Pharmaceuticals, LLC, Apotex Corp., Apotex Inc., Aurobindo Pharma Ltd., Aurobindo Pharma USA Inc., Aurolife Pharma LLC, Cadila Healthcare, Limited, Hetero Drugs Limited, Hetero Labs Limited, Hetero USA, Inc., Intas Pharmaceuticals Limited, Lupin Atlantis Holdings S.A., Lupin Limited, Lupin Pharmaceuticals, Inc., Mylan Inc., Mylan Pharmaceuticals Inc., Torrent Pharma Inc., Torrent Pharmaceuticals Limited and Zydus Pharmaceuticals USA, Inc.. designating Lawrence Sung as arguing attorney. Designated time for argument: 15 minutes. Designated time for rebuttal: 0 minutes. Service of other counsel by Notice of Docket Activity from this entry. [443861] [Lawrence Sung] [Entered: 07/03/2017 01:19 PM] (0) |
| Jun 30, 2017 | 154 | MOTION of Appellant Otsuka Pharmaceutical Co., Ltd. and Appellees Apotex Corp. and Apotex Inc. to withdraw party, Apotex Corp. and Apotex Inc., as a party to this appeal. Any response is due within 10 days of service [Consent: unopposed]. Service: 06/30/2017 by email. [443536] [James Monroe] [Entered: 06/30/2017 02:27 PM] (7) |
| Jun 15, 2017 | 150 | Response to oral argument order from the Appellees Accord Healthcare, Inc., Ajanta Pharma Limited, Ajanta Pharma USA Inc., Alembic Pharmaceuticals Limited, Amneal Pharmaceuticals India Pvt. Ltd., Amneal Pharmaceuticals, LLC, Apotex Corp., Apotex Inc., Aurobindo Pharma Ltd., Aurobindo Pharma USA Inc., Aurolife Pharma LLC, Cadila Healthcare, Limited, Hetero Drugs Limited, Hetero Labs Limited, Hetero USA, Inc., Intas Pharmaceuticals Limited, Lupin Atlantis Holdings S.A., Lupin Limited, Lupin Pharmaceuticals, Inc., Mylan Inc., Mylan Pharmaceuticals Inc., Torrent Pharma Inc., Torrent Pharmaceuticals Limited and Zydus Pharmaceuticals USA, Inc.. designating Joseph T. Jaros as arguing attorney. Designated time for argument: 12 minutes. Designated time for rebuttal: 3 minutes. Service of other counsel by Notice of Docket Activity from this entry. [439685] [William Rakoczy] [Entered: 06/15/2017 03:01 PM] (0) |
| Jun 15, 2017 | 151 | Response to oral argument order from the Appellant Otsuka Pharmaceutical Co., Ltd.. designating James B. Monroe as arguing attorney. Designated time for argument: 10 minutes. Designated time for rebuttal: 5 minutes. Service of other counsel by Notice of Docket Activity from this entry. [439701] [James Monroe] [Entered: 06/15/2017 03:22 PM] (0) |
| Jun 15, 2017 | 152 | CLERK'S OFFICE QUALITY CONTROL MESSAGE: re:calendar response Docket No. [150], ERROR: Counsel on behalf of appellees Accord Healthcare, Inc., Ajanta Pharma Limited, Ajanta Pharma USA Inc., Alembic Pharmaceuticals Limited, Amneal Pharmaceuticals India Pvt. Ltd., Amneal Pharmaceuticals, LLC, Apotex Corp., Apotex Inc., Aurobindo Pharma Ltd., Aurobindo Pharma USA Inc., Aurolife Pharma LLC, Cadila Healthcare, Limited, Hetero Drugs Limited, Hetero Labs Limited, Hetero USA, Inc., Intas Pharmaceuticals Limited, Lupin Atlantis Holdings S.A., Lupin Limited, Lupin Pharmaceuticals, Inc., Mylan Inc., Mylan Pharmaceuticals Inc., Torrent Pharma Inc., Torrent Pharmaceuticals Limited and Zydus Pharmaceuticals USA, Inc. submitted a response to oral argument order designating 12 minutes for argument and 3 minutes for rebuttal. The oral argument order issued with the notice of calendaring states that appellees may not divide argument time. CORRECTION: Please promptly submit a corrected response. [439740] [JAB] [Entered: 06/15/2017 03:56 PM] (0) |
| Jun 15, 2017 | 153 | CORRECTED Response to oral argument order from the Appellees Accord Healthcare, Inc., Ajanta Pharma Limited, Ajanta Pharma USA Inc., Alembic Pharmaceuticals Limited, Amneal Pharmaceuticals India Pvt. Ltd., Amneal Pharmaceuticals, LLC, Apotex Corp., Apotex Inc., Aurobindo Pharma Ltd., Aurobindo Pharma USA Inc., Aurolife Pharma LLC, Cadila Healthcare, Limited, Hetero Drugs Limited, Hetero Labs Limited, Hetero USA, Inc., Intas Pharmaceuticals Limited, Lupin Atlantis Holdings S.A., Lupin Limited, Lupin Pharmaceuticals, Inc., Mylan Inc., Mylan Pharmaceuticals Inc., Torrent Pharma Inc., Torrent Pharmaceuticals Limited and Zydus Pharmaceuticals USA, Inc.. designating Joseph T. Jaros as arguing attorney. Designated time for argument: 15 minutes. Designated time for rebuttal: 0 minutes. Service of other counsel by Notice of Docket Activity from this entry. [439759] [William Rakoczy] [Entered: 06/15/2017 04:06 PM] (0) |
| Jun 12, 2017 | 149 | Amended Certificate of Interest for the Appellees Mylan Inc. and Mylan Pharmaceuticals Inc.. Service: 06/12/2017 by email. [438538] [Deepro Mukerjee] [Entered: 06/12/2017 05:10 PM] (2) |
| May 19, 2017 | 148 | NOTICE OF CALENDARING. Panel: 1707B. Case scheduled Jul 10, 2017 10:00 a.m. at the United States Court of Appeals for the Federal Circuit (Howard T. Markey National Courts Building, 717 Madison Place, N.W. Washington, DC 20439), Courtroom 203. Response to oral argument order due: 06/15/2017. Arguing counsel is required to check-in at the Clerk's Office, 4th Floor, Room 401, between 8:30 am and 9:30 am on the day of argument. Please review the Oral Argument Order. [432916] [JAB] [Entered: 05/19/2017 03:52 PM] (0) |
| Apr 26, 2017 | 147 | Entry of appearance for Travis J. Iams as of counsel for Appellees Mylan Inc. and Mylan Pharmaceuticals Inc.. Service: 04/26/2017 by email. [427231] [Travis Iams] [Entered: 04/26/2017 11:48 AM] (2) |
| Mar 15, 2017 | 145 | ORDER filed. The motion to withdraw ScieGen and Bactolac from 16-1975 [132] is granted. The revised official caption for 16-1962 et al is reflected in the order. The motion to withdraw 16-1965 [144] is granted. 16-1965 is dismissed. Each side shall bear its own costs in 16-1965. ISSUED AS A MANDATE (for 16-1965 only): March 15, 2017. Service: 03/15/2017 by clerk. [415615] [16-1962, 16-1965, 16-1975] [LMS] [Entered: 03/15/2017 10:33 AM] (3) |
| Mar 15, 2017 | 146 | Official caption revised to remove 3 parties (pursuant to 3/15 order of the court, appeal 16-1965 is dismissed). The official caption is reflected on the electronic docket under the listing of the parties and counsel. Service as of this date by Clerk of Court. [415840] [SJ] [Entered: 03/15/2017 04:29 PM] (0) |
| Mar 13, 2017 | 144 | MOTION of Appellant Otsuka Pharmaceutical Co., Ltd. and Appellees Huahai US Inc., Prinston Pharmaceutical Inc. and Solco Healthcare U.S., LLC to terminate cross/consolidated appeal. Any response is due within 10 days of service [Consent: unopposed]. Service: 03/13/2017 by email. [414974] [James Monroe] [Entered: 03/13/2017 03:49 PM] (7) |
| Mar 3, 2017 | 135 | Notice from Appellees Apotex Corp. and Apotex Inc. regarding conflicts with oral argument (March 6-10 & 13, 2017; April 3-7 & 10, 2017; May 1-5 & 8, 2017). Service: 03/03/2017 by email. [412410] [William Rakoczy] [Entered: 03/03/2017 02:36 PM] (3) |
| Mar 3, 2017 | 136 | Notice from Appellees Accord Healthcare, Inc. and Intas Pharmaceuticals Limited regarding conflicts with oral argument (March 6-13, 2017; April 10, 2017). Service: 03/03/2017 by email. [412415] [Paul Braier] [Entered: 03/03/2017 02:43 PM] (2) |
| Mar 3, 2017 | 137 | Notice from Appellees Cadila Healthcare, Limited and Zydus Pharmaceuticals USA, Inc. regarding conflicts with oral argument (April 6, 7 & 10, 2017). Service: 03/03/2017 by email. [412426] [Chad Landmon] [Entered: 03/03/2017 02:56 PM] (2) |
| Mar 3, 2017 | 138 | Notice from Appellees Huahai US Inc., Prinston Pharmaceutical Inc. and Solco Healthcare U.S., LLC regarding conflicts with oral argument (None.). Service: 03/03/2017 by email. [412457] [Scott Cunning] [Entered: 03/03/2017 03:24 PM] (2) |
| Mar 3, 2017 | 139 | Notice from Appellees Amneal Pharmaceuticals India Pvt. Ltd. and Amneal Pharmaceuticals, LLC regarding conflicts with oral argument (May 1-8). Service: 03/03/2017 by email. [412485] [Ronald Daignault] [Entered: 03/03/2017 04:00 PM] (2) |
| Mar 3, 2017 | 140 | Notice from Appellees Mylan Inc. and Mylan Pharmaceuticals Inc. regarding conflicts with oral argument (None). Service: 03/03/2017 by email. [412498] [Deepro Mukerjee] [Entered: 03/03/2017 04:15 PM] (1) |
| Mar 3, 2017 | 141 | Notice from Appellees Aurobindo Pharma Ltd., Aurobindo Pharma USA Inc. and Aurolife Pharma LLC regarding conflicts with oral argument (No conflicts). Service: 03/03/2017 by email. [412512] [Brian Higgins] [Entered: 03/03/2017 04:41 PM] (2) |
| Mar 3, 2017 | 142 | Notice from Appellees Ajanta Pharma Limited and Ajanta Pharma USA Inc. regarding conflicts with oral argument (none). Service: 03/03/2017 by email. [412553] [Helen Ji] [Entered: 03/03/2017 07:11 PM] (1) |
| Mar 3, 2017 | 143 | Notice from Appellant Otsuka Pharmaceutical Co., Ltd. regarding conflicts with oral argument (April 3-7 & 10, 2017; May 1-5 & 8, 2017). Service: 03/03/2017 by email. [412563] [James Monroe] [Entered: 03/03/2017 08:41 PM] (2) |
| Mar 2, 2017 | 133 | Entry of appearance for Chandrika Vira as of counsel for Appellee Alembic Pharmaceuticals Limited. Service: 03/02/2017 by email. [411994] [Chandrika Vira] [Entered: 03/02/2017 01:54 PM] (2) |
| Mar 2, 2017 | 134 | 6 paper copies of the Confidential Joint Appendix (Vol. I-III) [127] received from Appellant Otsuka Pharmaceutical Co., Ltd. [412314] [KW] [Entered: 03/03/2017 11:40 AM] (0) |
| Feb 24, 2017 | 130 | Pursuant to Practice Note 34, counsel should advise the clerk of court of scheduling conflicts for the next three court weeks, or thereafter. When filing the notice of conflicts, counsel should docket the Notice Regarding Conflicts with Argument Dates event, which is found in the Calendar event category. The notice of conflict with oral argument is due on or before 03/03/2017. [410285] [SJ] [Entered: 02/24/2017 08:36 AM] (0) |
| Feb 24, 2017 | 131 | Notice of Rejection to Appellant Otsuka Pharmaceutical Co., Ltd. and Appellees Bactolac Pharmaceutical, Inc. and Sciegen Pharmaceuticals Inc., the following document(s): motion to terminate cross/consolidated appeal [126] is REJECTED for filing. Reason(s): incorrect relief selected. Service: 02/24/2017 by clerk. [410289] [SJ] [Entered: 02/24/2017 08:47 AM] (2) |
| Feb 24, 2017 | 132 | MOTION of Appellant Otsuka Pharmaceutical Co., Ltd. and Appellees Bactolac Pharmaceutical, Inc. and Sciegen Pharmaceuticals Inc. to withdraw party, Sciegen Pharmaceuticals Inc. and Bactolac Pharmaceutical, Inc. , as a party to this appeal. Any response is due within 10 days of service [Consent: unopposed]. Service: 02/24/2017 by email. [410580] [James Monroe] [Entered: 02/24/2017 04:30 PM] (7) |
| Feb 23, 2017 | 126 | MOTION of Appellant Otsuka Pharmaceutical Co., Ltd. and Appellees Bactolac Pharmaceutical, Inc. and Sciegen Pharmaceuticals Inc. to terminate cross/consolidated appeal. Any response is due within 10 days of service [Consent: unopposed]. Service: 02/23/2017 by email. [410086] [James Monroe] [Entered: 02/23/2017 01:57 PM] (7) |
| Feb 23, 2017 | 129 | CLERK'S OFFICE QUALITY CONTROL MESSAGE: re:appendix Brief Docket No. [128], appendix Brief Docket No. [127], ERROR: pursuant to FRAP 26(a)(4)(B), the appendix is late [due 2/21, submitted after midnight on the 22nd]. CORRECTION: the court sua sponte accepts the appendix as filed. THIS MESSAGE IS FOR INFORMATIONAL PURPOSES ONLY. [410243] [SJ] [Entered: 02/23/2017 05:14 PM] (0) |
| Feb 22, 2017 | 114 | TENDERED from Appellant Otsuka Pharmaceutical Co., Ltd.. Title: JOINT APPENDIX. Service: 02/21/2017 by email. [409452] [James Monroe] [Entered: 02/22/2017 12:25 AM] (1840) |
| Feb 22, 2017 | 115 | TENDERED from Appellant Otsuka Pharmaceutical Co., Ltd.. Title: CONFIDENTIAL JOINT APPENDIX Service: 02/21/2017 by email. [409453] [James Monroe] [Entered: 02/22/2017 12:36 AM] (0) |
| Feb 22, 2017 | 116 | Certificate of Compliance with Fed. Cir. R. 11(d) for Appellant Otsuka Pharmaceutical Co., Ltd.. Service: 02/21/2017 by email. [409454] [James Monroe] [Entered: 02/22/2017 12:51 AM] (0) |
| Feb 22, 2017 | 117 | NOTICE OF DEFICIENCY: The party document Document No. [116] filed by Appellant Otsuka Pharmaceutical Co., Ltd. in 16-1962 is submitted using the incorrect event and therefore cannot be accepted for filing at this time. You are being afforded the opportunity to correct the deficiency ['certificate of compliance with rule 11d' can be found under the 'forms and certificates' filing category]. At the discretion of the court, the corrected document may be accepted for filing if received before midnight (EST) on the date of this notice. [409496] [SJ] [Entered: 02/22/2017 09:09 AM] (0) |
| Feb 22, 2017 | 118 | Certificate of Compliance with Fed. Cir. R. 11(d) (Trial Court) for Appellees Lupin Atlantis Holdings S.A., Lupin Limited and Lupin Pharmaceuticals, Inc.. Service: 02/22/2017 by email. [409514] [Clifford Katz] [Entered: 02/22/2017 09:38 AM] (4) |
| Feb 22, 2017 | 119 | Certificate of Compliance with Fed. Cir. R. 11(d) (Trial Court) for Appellees Accord Healthcare, Inc. and Intas Pharmaceuticals Limited. Service: 02/22/2017 by email. [409521] [Paul Braier] [Entered: 02/22/2017 09:49 AM] (4) |
| Feb 22, 2017 | 120 | Certificate of Compliance with Fed. Cir. R. 11(d) (Trial Court) for Appellee Zydus Pharmaceuticals USA, Inc.. Service: 02/22/2017 by email. [409526] [Chad Landmon] [Entered: 02/22/2017 10:00 AM] (4) |
| Feb 22, 2017 | 121 | Certificate of Compliance with Fed. Cir. R. 11(d) (Trial Court) for Appellant Otsuka Pharmaceutical Co., Ltd.. Service: 02/22/2017 by email. [409620] [James Monroe] [Entered: 02/22/2017 12:31 PM] (6) |
| Feb 22, 2017 | 122 | Certificate of Compliance with Fed. Cir. R. 11(d) (Trial Court) for Appellees Apotex Corp. and Apotex Inc.. Service: 02/22/2017 by email. [409640] [William Rakoczy] [Entered: 02/22/2017 01:09 PM] (5) |
| Feb 22, 2017 | 123 | 6 paper copies of the Reply Brief [108] received from Appellant Otsuka Pharmaceutical Co., Ltd. [409655] [KW] [Entered: 02/22/2017 01:23 PM] (0) |
| Feb 22, 2017 | 124 | Certificate of Compliance with Fed. Cir. R. 11(d) (Trial Court) for Appellees Bactolac Pharmaceutical, Inc. and Sciegen Pharmaceuticals Inc.. Service: 02/22/2017 by email. [409727] [Frank Rodriguez] [Entered: 02/22/2017 03:00 PM] (3) |
| Feb 22, 2017 | 125 | Certificate of Compliance with Fed. Cir. R. 11(d) (Trial Court) for Appellee Alembic Pharmaceuticals Limited. Service: 02/22/2017 by email. [409831] [Dennies Varughese] [Entered: 02/22/2017 08:40 PM] (6) |
| Feb 22, 2017 | 127 | CONFIDENTIAL JOINT APPENDIX FILED (3 vols.) for Otsuka Pharmaceutical Co., Ltd. [115]. Number of Pages: 1840. Service: 02/21/2017 by email. The paper copies of the brief should be received by the court on or before 03/02/2017. [410221] [SJ] [Entered: 02/23/2017 04:49 PM] (0) |
| Feb 22, 2017 | 128 | APPENDIX FILED for Otsuka Pharmaceutical Co., Ltd. [114]. Number of Pages: 1840. Service: 02/22/2017 by email. The paper copies of the brief should be received by the court on or before 03/02/2017. [410241] [SJ] [Entered: 02/23/2017 05:10 PM] (1840) |
| Feb 21, 2017 | 109 | Certificate of Compliance with Fed. Cir. R. 11(d) (Trial Court) for Appellees Aurobindo Pharma Ltd., Aurobindo Pharma USA Inc. and Aurolife Pharma LLC. Service: 02/21/2017 by email. [409411] [Brian Higgins] [Entered: 02/21/2017 07:00 PM] (5) |
| Feb 21, 2017 | 110 | Certificate of Compliance with Fed. Cir. R. 11(d) (Trial Court) for Appellees Torrent Pharma Inc. and Torrent Pharmaceuticals Limited. Service: 02/21/2017 by email. [409428] [Rachel Hunnicutt] [Entered: 02/21/2017 08:10 PM] (4) |
| Feb 21, 2017 | 111 | Certificate of Compliance with Fed. Cir. R. 11(d) (Trial Court) for Appellees Hetero Drugs Limited, Hetero Labs Limited and Hetero USA, Inc.. Service: 02/21/2017 by email. [409435] [Phoebe Fischer-Groban] [Entered: 02/21/2017 10:37 PM] (3) |
| Feb 21, 2017 | 112 | Statement of Compliance with Fed. Cir. R. 33 for Appellant Otsuka Pharmaceutical Co., Ltd. and Appellee Sciegen Pharmaceuticals Inc.. Service: 02/21/2017 by email. [409449] [James Monroe] [Entered: 02/21/2017 11:51 PM] (6) |
| Feb 21, 2017 | 113 | Statement of Compliance with Fed. Cir. R. 33 for Appellant Otsuka Pharmaceutical Co., Ltd. and Appellees Accord Healthcare, Inc., Ajanta Pharma Limited, Ajanta Pharma USA Inc., Alembic Pharmaceuticals Limited, Amneal Pharmaceuticals India Pvt. Ltd., Amneal Pharmaceuticals, LLC, Apotex Corp., Apotex Inc., Aurobindo Pharma Ltd., Aurobindo Pharma USA Inc., Aurolife Pharma LLC, Cadila Healthcare, Limited, Hetero Drugs Limited, Hetero Labs Limited, Hetero USA, Inc., Huahai US Inc., Intas Pharmaceuticals Limited, Lupin Atlantis Holdings S.A., Lupin Limited, Lupin Pharmaceuticals, Inc., Mylan Inc., Mylan Pharmaceuticals Inc., Prinston Pharmaceutical Inc., Solco Healthcare U.S., LLC, Torrent Pharma Inc., Torrent Pharmaceuticals Limited and Zydus Pharmaceuticals USA, Inc.. Service: 02/21/2017 by email. [409450] [James Monroe] [Entered: 02/21/2017 11:52 PM] (22) |
| Feb 13, 2017 | 107 | TENDERED from Appellant Otsuka Pharmaceutical Co., Ltd.. Title: REPLY BRIEF. Service: 02/13/2017 by email. [407073] [James Monroe] [Entered: 02/13/2017 08:00 PM] (38) |
| Feb 13, 2017 | 108 | REPLY BRIEF FILED for Appellant Otsuka Pharmaceutical Co., Ltd. [107]. Number of Pages: 29. Service: 02/13/2017 by email. The paper copies of the brief should be received by the court on or before 02/22/2017. Appendix is due 02/21/2017. [407251] [SJ] [Entered: 02/14/2017 11:39 AM] (38) |
| Dec 23, 2016 | 106 | **TEXT ONLY** ORDER granting motion to extend time to file the reply brief [105] filed by Appellant Otsuka Pharmaceutical Co., Ltd.. The reply brief is due 02/13/2017. Service as of this date by Clerk of Court. This order has been issued without an attached document and is official and binding. [394110] [MJL] [Entered: 12/23/2016 09:04 AM] (0) |
| Dec 22, 2016 | 104 | Amended Certificate of Interest for the Appellant Otsuka Pharmaceutical Co., Ltd.. Service: 12/22/2016 by email. [393863] [James Monroe] [Entered: 12/22/2016 04:11 PM] (3) |
| Dec 22, 2016 | 105 | MOTION of Appellant Otsuka Pharmaceutical Co., Ltd. to extend the time to 02/13/2017 at 11:59 pm to file the reply brief. Any response is due within 10 days of service [Consent: unopposed]. Service: 12/22/2016 by email. [393909] [James Monroe] [Entered: 12/22/2016 04:36 PM] (9) |
| Dec 21, 2016 | 103 | 6 paper copies of the Confidential Response Brief [100] received from Appellees Accord Healthcare, Inc., Ajanta Pharma Limited, Ajanta Pharma USA Inc., et al. [393251] [KW] [Entered: 12/21/2016 03:16 PM] (0) |
| Dec 19, 2016 | 102 | Entry of appearance for Helen H. Ji as of counsel for Appellees Ajanta Pharma Limited and Ajanta Pharma USA Inc.. Service: 12/19/2016 by email. [392441] [Helen Ji] [Entered: 12/19/2016 06:23 PM] (2) |
| Dec 16, 2016 | 98 | TENDERED from Appellees Accord Healthcare, Inc., Ajanta Pharma Limited, Ajanta Pharma USA Inc., Alembic Pharmaceuticals Limited, Amneal Pharmaceuticals India Pvt. Ltd., Amneal Pharmaceuticals, LLC, Apotex Corp., Apotex Inc., Aurobindo Pharma Ltd., Aurobindo Pharma USA Inc., Aurolife Pharma LLC, Bactolac Pharmaceutical, Inc., Cadila Healthcare, Limited, Hetero Drugs Limited, Hetero Labs Limited, Hetero USA, Inc., Huahai US Inc., Intas Pharmaceuticals Limited, Lupin Atlantis Holdings S.A., Lupin Limited, Lupin Pharmaceuticals, Inc., Mylan Inc., Mylan Pharmaceuticals Inc., Prinston Pharmaceutical Inc., Sciegen Pharmaceuticals Inc., Solco Healthcare U.S., LLC, Torrent Pharma Inc., Torrent Pharmaceuticals Limited and Zydus Pharmaceuticals USA, Inc.. Title: CONFIDENTIAL RESPONSE BRIEF Service: 12/16/2016 by email. [392016] [William Rakoczy] [Entered: 12/16/2016 08:36 PM] (0) |
| Dec 16, 2016 | 99 | TENDERED from Appellees Accord Healthcare, Inc., Ajanta Pharma Limited, Ajanta Pharma USA Inc., Alembic Pharmaceuticals Limited, Amneal Pharmaceuticals India Pvt. Ltd., Amneal Pharmaceuticals, LLC, Apotex Corp., Apotex Inc., Aurobindo Pharma Ltd., Aurobindo Pharma USA Inc., Aurolife Pharma LLC, Bactolac Pharmaceutical, Inc., Cadila Healthcare, Limited, Hetero Drugs Limited, Hetero Labs Limited, Hetero USA, Inc., Huahai US Inc., Intas Pharmaceuticals Limited, Lupin Atlantis Holdings S.A., Lupin Limited, Lupin Pharmaceuticals, Inc., Mylan Inc., Mylan Pharmaceuticals Inc., Prinston Pharmaceutical Inc., Sciegen Pharmaceuticals Inc., Solco Healthcare U.S., LLC, Torrent Pharma Inc., Torrent Pharmaceuticals Limited and Zydus Pharmaceuticals USA, Inc.. Title: RESPONSE BRIEF. Service: 12/16/2016 by email. [392018] [William Rakoczy] [Entered: 12/16/2016 09:11 PM] (111) |
| Dec 16, 2016 | 100 | CONFIDENTIAL BRIEF FILED for Appellees Accord Healthcare, Inc., Ajanta Pharma Limited, et al. [98]. Number of Pages: 67. Service: 12/16/2016 by email. The paper copies of the brief should be received by the court on or before 12/27/2016. [392379] [CAB] [Entered: 12/19/2016 04:22 PM] (0) |
| Dec 16, 2016 | 101 | BRIEF FILED for Appellees Accord Healthcare, Inc., Ajanta Pharma Limited, et al. [99]. Number of Pages: 67. Service: 12/16/2016 by email. Appellant Otsuka Pharmaceutical Co., Ltd.'s reply brief is due 12/30/2016. [392400] [CAB] [Entered: 12/19/2016 04:50 PM] (111) |
| Dec 8, 2016 | 97 | Corrected Entry of appearance for Margaret E. Ives as principal counsel for Appellees Hetero Drugs Limited, Hetero Labs Limited and Hetero USA, Inc.. Service: 12/08/2016 by email. [389635] [Margaret Ives] [Entered: 12/08/2016 05:46 PM] (2) |
| Sep 26, 2016 | 94 | **TEXT ONLY** ORDER granting motion to withdraw attorney ROY CHAMCHARAS [92] filed by Appellees Apotex Inc. and Apotex Corp. Service as of this date by Clerk of Court. This order has been issued without an attached document and is official and binding. [369085] [AT] [Entered: 09/26/2016 08:44 AM] (0) |
| Sep 26, 2016 | 95 | **TEXT ONLY** ORDER granting motion to extend time to file appellees' principal brief [93] filed by Appellees Apotex Inc. and Apotex Corp. The brief(s) for all appellees are due on 12/16/2016. Service as of this date by Clerk of Court. This order has been issued without an attached document and is official and binding. [369093] [AT] [Entered: 09/26/2016 08:54 AM] (0) |
| Sep 26, 2016 | 96 | 6 paper copies of the Opening Brief [91] received from Appellant Otsuka Pharmaceutical Co., Ltd. [369301] [KW] [Entered: 09/26/2016 03:40 PM] (0) |
| Sep 23, 2016 | 92 | MOTION of Appellees Apotex Corp. and Apotex Inc. to withdraw counsel Roy Chamcharas. Response/Opposition is due 10/06/2016 [Consent: unopposed]. Service: 09/23/2016 by email. [369014] [William Rakoczy] [Entered: 09/23/2016 04:42 PM] (6) |
| Sep 23, 2016 | 93 | MOTION of Appellees Apotex Corp. and Apotex Inc. to extend the time to 12/16/2016 to file the appellee/respondent/cross-appellant's principal brief. Response/Opposition is due 10/06/2016 [Consent: unopposed]. Service: 09/23/2016 by email. [369021] [William Rakoczy] [Entered: 09/23/2016 04:57 PM] (10) |
| Sep 19, 2016 | 90 | TENDERED from Appellant Otsuka Pharmaceutical Co., Ltd.. Title: CORRECTED OPENING BRIEF. Service: 09/19/2016 by email. [367565] [James Monroe] [Entered: 09/19/2016 07:20 PM] (284) |
| Sep 19, 2016 | 91 | CORRECTED BRIEF FILED for Appellant Otsuka Pharmaceutical Co., Ltd. [90]. Number of Pages: 62. Service: 09/19/2016 by email. The paper copies of the brief should be received by the court on or before 09/26/2016. [367755] [AT] [Entered: 09/20/2016 12:47 PM] (284) |
| Sep 7, 2016 | 89 | NOTICE OF REJECTION: The Brief for Plaintiff-Appellant Otsuka Pharmaceutical Co., Ltd. [88], is not in compliance with the rules of this court and is therefore rejected for filing. See attached notice for explanation. Appellant's corrected brief is due 09/21/2016. Appellees' briefs are due 10/17/2016. Service as of this date by Clerk of Court. [364668] [AT] [Entered: 09/07/2016 11:25 AM] (2) |
| Sep 6, 2016 | 88 | TENDERED from Appellant Otsuka Pharmaceutical Co., Ltd.. Title: OPENING BRIEF. Service: 09/06/2016 by email. [364563] This brief has been rejected for filing. See Doc. No. [89] [James Monroe] [Entered: 09/06/2016 09:35 PM] (0) |
| Aug 26, 2016 | 87 | Entry of appearance for Lance A. Soderstrom as of counsel for Appellees Mylan Inc. and Mylan Pharmaceuticals Inc.. Service: 08/26/2016 by email. [362476] [Lance Soderstrom] [Entered: 08/26/2016 05:44 PM] (2) |
| Aug 16, 2016 | 85 | ORDER filed. The motion [84] is granted. 2016-1967 and 2016-1969 are dismissed. The revised official caption for 2016-1962 et al. is reflected in the order. Each side shall bear its own costs in 2016-1967 and 2016-1969. ISSUED AS A MANDATE (as to 2016-1967 and 2016-1969 only): August 16, 2016. Service: 08/16/2016 by clerk. [359202] [16-1962, 16-1967, 16-1969] [LMS] [Entered: 08/16/2016 12:42 PM] (3) |
| Aug 16, 2016 | 86 | Official caption revised pursuant to the court's order filed 8/16/16. The official caption is reflected on the electronic docket under the listing of the parties and counsel. Service as of this date by Clerk of Court. [359406] [AT] [Entered: 08/16/2016 03:35 PM] (0) |
| Aug 11, 2016 | 84 | MOTION of Appellant Otsuka Pharmaceutical Co., Ltd. and Appellee Teva Pharmaceuticals USA, Inc. to terminate cross/consolidated appeal. Response/Opposition is due 08/25/2016 [Consent: unopposed]. Service: 08/11/2016 by email. [358224] [James Monroe] [Entered: 08/11/2016 06:43 PM] (7) |
| Jun 29, 2016 | 83 | **TEXT ONLY** ORDER granting motion to extend time to file appellant's principal brief [82] filed by Appellant Otsuka Pharmaceutical Co., Ltd. Brief due 09/06/2016. Service as of this date by Clerk of Court. This order has been issued without an attached document and is official and binding. [347509] [SJ] [Entered: 06/29/2016 03:58 PM] (0) |
| Jun 28, 2016 | 80 | Amended Entry of appearance for Jeffrey A. Freeman as of counsel for Appellant Otsuka Pharmaceutical Co., Ltd.. Service: 06/28/2016 by email. [347071] [James Monroe] [Entered: 06/28/2016 02:48 PM] (2) |
| Jun 28, 2016 | 81 | Amended Certificate of Interest for the Appellant Otsuka Pharmaceutical Co., Ltd.. Service: 06/28/2016 by email. [347158] [James Monroe] [Entered: 06/28/2016 05:03 PM] (3) |
| Jun 28, 2016 | 82 | MOTION of Appellant Otsuka Pharmaceutical Co., Ltd. to extend the time to 09/06/2016 at 11:59 pm to file the appellant/petitioner's principal brief. Response/Opposition is due 07/11/2016 [Consent: unopposed]. Service: 06/28/2016 by email. [347167] [James Monroe] [Entered: 06/28/2016 05:15 PM] (9) |
| Jun 16, 2016 | 79 | Entry of appearance for Charles T. Collins-Chase as of counsel for Appellant Otsuka Pharmaceutical Co., Ltd.. Service: 06/16/2016 by email. [344434] [James Monroe] [Entered: 06/16/2016 09:28 PM] (2) |
| May 23, 2016 | 78 | Entry of appearance for Dennies Varughese as principal counsel for Appellee Alembic Pharmaceuticals Limited. Service: 05/23/2016 by email. [337681] [Dennies Varughese] [Entered: 05/23/2016 04:55 PM] (2) |
| May 20, 2016 | 77 | Entry of appearance for Phoebe Fischer-Groban as of counsel for Appellees Hetero Drugs Limited, Hetero Labs Limited and Hetero USA, Inc.. Service: 05/20/2016 by email. [337073] [Phoebe Fischer-Groban] [Entered: 05/20/2016 11:13 AM] (2) |
| May 18, 2016 | 76 | NOTICE OF DEFICIENCY: The attorney entry of appearance Document No. [58] filed by Appellees Hetero Drugs Limited, Hetero Labs Limited and Hetero USA, Inc. in 16-1962 is not signed and therefore cannot be accepted for filing at this time. You are being afforded the opportunity to correct the deficiency. At the discretion of the court, the corrected document may be accepted for filing if received before midnight (EST) on the date of this notice. [336438] [SJ] [Entered: 05/18/2016 01:31 PM] (0) |
| May 17, 2016 | 15 | Docketing Statement for the Appellees Ajanta Pharma Limited and Ajanta Pharma USA Inc.. Service: 05/17/2016 by email. [335843] [Sailesh Patel] [Entered: 05/17/2016 11:08 AM] (3) |
| May 17, 2016 | 16 | Certificate of Interest for the Appellees Ajanta Pharma Limited and Ajanta Pharma USA Inc.. Service: 05/17/2016 by email. [335847] [Sailesh Patel] [Entered: 05/17/2016 11:10 AM] (0) |
| May 17, 2016 | 17 | Entry of appearance for Sailesh K. Patel as of counsel for Appellees Ajanta Pharma Limited and Ajanta Pharma USA Inc.. Service: 05/17/2016 by email. [335854] [Sailesh Patel] [Entered: 05/17/2016 11:16 AM] (1) |
| May 17, 2016 | 18 | Entry of appearance for Ronald M. Daignault as principal counsel for Appellees Amneal Pharmaceuticals India Pvt. Ltd. and Amneal Pharmaceuticals, LLC. Service: 05/17/2016 by email. [335859] [Ronald Daignault] [Entered: 05/17/2016 11:23 AM] (2) |
| May 17, 2016 | 19 | Entry of appearance for Paul A. Braier as principal counsel for Appellees Accord Healthcare Inc. and Intas Pharmaceuticals Limited. Service: 05/17/2016 by email. [335860] [Paul Braier] [Entered: 05/17/2016 11:25 AM] (2) |
| May 17, 2016 | 20 | Entry of appearance for Scott A. Cunning II as principal counsel for Appellees Huahai US Inc., Prinston Pharmaceutical Inc. and Solco Healthcare U.S., LLC. Service: 05/17/2016 by email. [335861] [Scott Cunning] [Entered: 05/17/2016 11:26 AM] (2) |
| May 17, 2016 | 21 | Entry of appearance for P. Branko Pejic as of counsel for Appellees Accord Healthcare Inc. and Intas Pharmaceuticals Limited. Service: 05/17/2016 by email. [335862] [Paul Braier] [Entered: 05/17/2016 11:26 AM] (2) |
| May 17, 2016 | 22 | Corrected Entry of appearance for Sailesh K. Patel as principal counsel for Appellees Ajanta Pharma Limited and Ajanta Pharma USA Inc.. Service: 05/17/2016 by email. [335864] [Sailesh Patel] [Entered: 05/17/2016 11:26 AM] (0) |
| May 17, 2016 | 23 | Certificate of Interest for the Appellee Huahai US Inc.. Service: 05/17/2016 by email. [335865] [Scott Cunning] [Entered: 05/17/2016 11:27 AM] (2) |
| May 17, 2016 | 24 | Certificate of Interest for the Appellees Accord Healthcare Inc. and Intas Pharmaceuticals Limited. Service: 05/17/2016 by email. [335866] [Paul Braier] [Entered: 05/17/2016 11:27 AM] (2) |
| May 17, 2016 | 25 | Docketing Statement for the Appellees Amneal Pharmaceuticals India Pvt. Ltd. and Amneal Pharmaceuticals, LLC. Service: 05/17/2016 by email. [335868] [Ronald Daignault] [Entered: 05/17/2016 11:28 AM] (3) |
| May 17, 2016 | 26 | Certificate of Interest for the Appellee Prinston Pharmaceutical Inc.. Service: 05/17/2016 by email. [335870] [Scott Cunning] [Entered: 05/17/2016 11:28 AM] (2) |
| May 17, 2016 | 27 | Docketing Statement for the Appellees Accord Healthcare Inc. and Intas Pharmaceuticals Limited. Service: 05/17/2016 by email. [335871] [Paul Braier] [Entered: 05/17/2016 11:29 AM] (3) |
| May 17, 2016 | 28 | Certificate of Interest for the Appellee Solco Healthcare U.S., LLC. Service: 05/17/2016 by email. [335872] [Scott Cunning] [Entered: 05/17/2016 11:29 AM] (2) |
| May 17, 2016 | 29 | Certificate of Interest for the Appellees Amneal Pharmaceuticals India Pvt. Ltd. and Amneal Pharmaceuticals, LLC. Service: 05/17/2016 by email. [335873] [Ronald Daignault] [Entered: 05/17/2016 11:30 AM] (2) |
| May 17, 2016 | 30 | Docketing Statement for the Appellees Huahai US Inc., Prinston Pharmaceutical Inc. and Solco Healthcare U.S., LLC. Service: 05/17/2016 by email. [335875] [Scott Cunning] [Entered: 05/17/2016 11:31 AM] (4) |
| May 17, 2016 | 31 | Entry of appearance for Karen Z. Morris as of counsel for Appellees Amneal Pharmaceuticals India Pvt. Ltd. and Amneal Pharmaceuticals, LLC. Service: 05/17/2016 by email. [335880] [Karen Morris] [Entered: 05/17/2016 11:34 AM] (2) |
| May 17, 2016 | 32 | Entry of appearance for William A. Rakoczy as principal counsel for Appellees Apotex Corp. and Apotex Inc.. Service: 05/17/2016 by email. [335993] [William Rakoczy] [Entered: 05/17/2016 01:59 PM] (2) |
| May 17, 2016 | 33 | Entry of appearance for Deanne M. Mazzochi as of counsel for Appellees Apotex Corp. and Apotex Inc.. Service: 05/17/2016 by email. [335997] [William Rakoczy] [Entered: 05/17/2016 02:00 PM] (2) |
| May 17, 2016 | 34 | Entry of appearance for Joseph T. Jaros as of counsel for Appellees Apotex Corp. and Apotex Inc.. Service: 05/17/2016 by email. [336003] [William Rakoczy] [Entered: 05/17/2016 02:02 PM] (2) |
| May 17, 2016 | 35 | Entry of appearance for Roy Chamcharas as of counsel for Appellees Apotex Corp. and Apotex Inc.. Service: 05/17/2016 by email. [336005] [William Rakoczy] [Entered: 05/17/2016 02:03 PM] (2) |
| May 17, 2016 | 36 | Entry of appearance for Chad A. Landmon as principal counsel for Appellees Cadila Healthcare, Limited and Zydus Pharmaceuticals USA, Inc.. Service: 05/17/2016 by email. [336011] [Chad Landmon] [Entered: 05/17/2016 02:06 PM] (2) |
| May 17, 2016 | 37 | Certificate of Interest for the Appellees Apotex Corp. and Apotex Inc.. Service: 05/17/2016 by email. [336012] [William Rakoczy] [Entered: 05/17/2016 02:06 PM] (2) |
| May 17, 2016 | 38 | Docketing Statement for the Appellees Apotex Corp. and Apotex Inc.. Service: 05/17/2016 by email. [336014] [William Rakoczy] [Entered: 05/17/2016 02:07 PM] (3) |
| May 17, 2016 | 39 | Docketing Statement for the Appellees Cadila Healthcare, Limited and Zydus Pharmaceuticals USA, Inc.. Service: 05/17/2016 by email. [336016] [Chad Landmon] [Entered: 05/17/2016 02:08 PM] (3) |
| May 17, 2016 | 40 | NOTICE OF DEFICIENCY: The attorney entry of appearance Document No. [22] and certificate of interest Document No. [16] filed by Appellees Ajanta Pharma Limited and Ajanta Pharma USA Inc. in 16-1962 is without a proper/complete proof of service and therefore cannot be accepted for filing at this time. You are being afforded the opportunity to correct the deficiency. At the discretion of the court, the corrected document may be accepted for filing if received before midnight (EST) on the date of this notice. [336017] [SJ] [Entered: 05/17/2016 02:10 PM] (0) |
| May 17, 2016 | 41 | Certificate of Interest for the Appellees Cadila Healthcare, Limited and Zydus Pharmaceuticals USA, Inc.. Service: 05/17/2016 by email. [336019] [Chad Landmon] [Entered: 05/17/2016 02:10 PM] (3) |
| May 17, 2016 | 42 | Entry of appearance for Frank D. Rodriguez as principal counsel for Appellees Bactolac Pharmaceutical, Inc. and Sciegen Pharmaceuticals Inc.. Service: 05/17/2016 by email. [336020] [Frank Rodriguez] [Entered: 05/17/2016 02:10 PM] (2) |
| May 17, 2016 | 43 | Certificate of Interest for the Appellees Bactolac Pharmaceutical, Inc. and Sciegen Pharmaceuticals Inc.. Service: 05/17/2016 by email. [336022] [Frank Rodriguez] [Entered: 05/17/2016 02:11 PM] (2) |
| May 17, 2016 | 44 | Entry of appearance for Delphine W. Knight Brown as of counsel for Appellees Cadila Healthcare, Limited and Zydus Pharmaceuticals USA, Inc.. Service: 05/17/2016 by email. [336023] [Chad Landmon] [Entered: 05/17/2016 02:12 PM] (2) |
| May 17, 2016 | 45 | Docketing Statement for the Appellees Bactolac Pharmaceutical, Inc. and Sciegen Pharmaceuticals Inc.. Service: 05/17/2016 by email. [336025] [Frank Rodriguez] [Entered: 05/17/2016 02:13 PM] (4) |
| May 17, 2016 | 46 | Entry of appearance for Ellen T. Lowenthal as of counsel for Appellees Bactolac Pharmaceutical, Inc. and Sciegen Pharmaceuticals Inc.. Service: 05/17/2016 by email. [336031] [Ellen Lowenthal] [Entered: 05/17/2016 02:21 PM] (2) |
| May 17, 2016 | 47 | Entry of appearance for Douglass C. Hochstetler as principal counsel for Appellees Lupin Atlantis Holdings S.A., Lupin Limited and Lupin Pharmaceuticals, Inc.. Service: 05/17/2016 by email. [336061] [Douglass Hochstetler] [Entered: 05/17/2016 03:02 PM] (2) |
| May 17, 2016 | 48 | Entry of appearance for Clifford Katz as of counsel for Appellees Lupin Atlantis Holdings S.A., Lupin Limited and Lupin Pharmaceuticals, Inc.. Service: 05/17/2016 by email. [336078] [Clifford Katz] [Entered: 05/17/2016 03:10 PM] (2) |
| May 17, 2016 | 49 | Certificate of Interest for the Appellee Lupin Limited. Service: 05/17/2016 by email. [336090] [Clifford Katz] [Entered: 05/17/2016 03:16 PM] (2) |
| May 17, 2016 | 50 | Certificate of Interest for the Appellee Lupin Pharmaceuticals, Inc.. Service: 05/17/2016 by email. [336091] [Clifford Katz] [Entered: 05/17/2016 03:17 PM] (2) |
| May 17, 2016 | 51 | Certificate of Interest for the Appellee Lupin Atlantis Holdings S.A.. Service: 05/17/2016 by email. [336092] [Clifford Katz] [Entered: 05/17/2016 03:18 PM] (2) |
| May 17, 2016 | 52 | Docketing Statement for the Appellees Lupin Atlantis Holdings S.A., Lupin Limited and Lupin Pharmaceuticals, Inc.. Service: 05/17/2016 by email. [336094] [Clifford Katz] [Entered: 05/17/2016 03:19 PM] (3) |
| May 17, 2016 | 53 | Entry of appearance for Brian Wm. Higgins, Esq. as principal counsel for Appellees Aurobindo Pharma Ltd., Aurobindo Pharma USA Inc. and Aurolife Pharma LLC. Service: 05/17/2016 by email. [336105] [Brian Higgins] [Entered: 05/17/2016 03:24 PM] (2) |
| May 17, 2016 | 54 | Certificate of Interest for the Appellees Aurobindo Pharma Ltd., Aurobindo Pharma USA Inc. and Aurolife Pharma LLC. Service: 05/17/2016 by email. [336114] [Brian Higgins] [Entered: 05/17/2016 03:29 PM] (2) |
| May 17, 2016 | 55 | Docketing Statement for the Appellees Aurobindo Pharma Ltd., Aurobindo Pharma USA Inc. and Aurolife Pharma LLC. Service: 05/17/2016 by email. [336119] [Brian Higgins] [Entered: 05/17/2016 03:32 PM] (4) |
| May 17, 2016 | 56 | Entry of appearance for Christopher K. Hu, Esquire as of counsel for Appellees Aurobindo Pharma Ltd., Aurobindo Pharma USA Inc. and Aurolife Pharma LLC. Service: 05/17/2016 by email. [336127] [Christopher Hu] [Entered: 05/17/2016 03:36 PM] (2) |
| May 17, 2016 | 57 | Entry of appearance for Gerard A. Haddad, Esquire as of counsel for Appellees Aurobindo Pharma Ltd., Aurobindo Pharma USA Inc. and Aurolife Pharma LLC. Service: 05/17/2016 by email. [336130] [Gerard Haddad] [Entered: 05/17/2016 03:40 PM] (2) |
| May 17, 2016 | 58 | Entry of appearance for Margaret E. Ives as principal counsel for Appellees Hetero Drugs Limited, Hetero Labs Limited and Hetero USA, Inc.. Service: 05/17/2016 by email. [336155] [Margaret Ives] [Entered: 05/17/2016 04:04 PM] (0) |
| May 17, 2016 | 59 | Certificate of Interest for the Appellees Hetero Drugs Limited, Hetero Labs Limited and Hetero USA, Inc.. Service: 05/17/2016 by email. [336156] [Margaret Ives] [Entered: 05/17/2016 04:04 PM] (2) |
| May 17, 2016 | 60 | Docketing Statement for the Appellees Hetero Drugs Limited, Hetero Labs Limited and Hetero USA, Inc.. Service: 05/17/2016 by email. [336158] [Margaret Ives] [Entered: 05/17/2016 04:05 PM] (3) |
| May 17, 2016 | 61 | Entry of appearance for Jon E. Wright as of counsel for Appellee Alembic Pharmaceuticals Limited. Service: 05/17/2016 by email. [336190] [Jon Wright] [Entered: 05/17/2016 04:52 PM] (2) |
| May 17, 2016 | 62 | Certificate of Interest for the Appellee Alembic Pharmaceuticals Limited. Service: 05/17/2016 by email. [336191] [Jon Wright] [Entered: 05/17/2016 04:53 PM] (2) |
| May 17, 2016 | 63 | Docketing Statement for the Appellee Alembic Pharmaceuticals Limited. Service: 05/17/2016 by email. [336193] [Jon Wright] [Entered: 05/17/2016 04:54 PM] (4) |
| May 17, 2016 | 64 | Entry of appearance for Deepro R. Mukerjee as principal counsel for Appellees Mylan Inc. and Mylan Pharmaceuticals Inc.. Service: 05/17/2016 by email. [336194] [Deepro Mukerjee] [Entered: 05/17/2016 05:04 PM] (2) |
| May 17, 2016 | 65 | Docketing Statement for the Appellees Mylan Inc. and Mylan Pharmaceuticals Inc.. Service: 05/17/2016 by email. [336198] [Deepro Mukerjee] [Entered: 05/17/2016 05:06 PM] (4) |
| May 17, 2016 | 66 | Certificate of Interest for the Appellees Mylan Inc. and Mylan Pharmaceuticals Inc.. Service: 05/17/2016 by email. [336199] [Deepro Mukerjee] [Entered: 05/17/2016 05:10 PM] (2) |
| May 17, 2016 | 67 | Corrected Certificate of Interest for the Appellees Ajanta Pharma Limited and Ajanta Pharma USA Inc.. Service: 05/17/2016 by email. [336204] [Sailesh Patel] [Entered: 05/17/2016 05:23 PM] (2) |
| May 17, 2016 | 68 | Corrected Entry of appearance for Sailesh K. Patel as principal counsel for Appellees Ajanta Pharma Limited and Ajanta Pharma USA Inc.. Service: 05/17/2016 by email. [336205] [Sailesh Patel] [Entered: 05/17/2016 05:25 PM] (2) |
| May 17, 2016 | 69 | Entry of appearance for James B. Monroe as principal counsel for Appellant Otsuka Pharmaceutical Co., Ltd.. Service: 05/17/2016 by email. [336210] [James Monroe] [Entered: 05/17/2016 05:47 PM] (2) |
| May 17, 2016 | 70 | Entry of appearance for Paul W. Browning as of counsel for Appellant Otsuka Pharmaceutical Co., Ltd.. Service: 05/17/2016 by email. [336212] [James Monroe] [Entered: 05/17/2016 05:50 PM] (2) |
| May 17, 2016 | 71 | Entry of appearance for Eric J. Fues as of counsel for Appellant Otsuka Pharmaceutical Co., Ltd.. Service: 05/17/2016 by email. [336214] [James Monroe] [Entered: 05/17/2016 05:53 PM] (2) |
| May 17, 2016 | 72 | Entry of appearance for Andrea Denise Main as of counsel for Appellant Otsuka Pharmaceutical Co., Ltd.. Service: 05/17/2016 by email. [336215] [James Monroe] [Entered: 05/17/2016 05:56 PM] (2) |
| May 17, 2016 | 73 | Entry of appearance for Jeffrey A. Freeman as of counsel for Appellant Otsuka Pharmaceutical Co., Ltd.. Service: 05/17/2016 by email. [336216] [James Monroe] [Entered: 05/17/2016 05:58 PM] (2) |
| May 17, 2016 | 74 | Certificate of Interest for the Appellant Otsuka Pharmaceutical Co., Ltd.. Service: 05/17/2016 by email. [336217] [James Monroe] [Entered: 05/17/2016 06:03 PM] (2) |
| May 17, 2016 | 75 | Docketing Statement for the Appellant Otsuka Pharmaceutical Co., Ltd.. Service: 05/17/2016 by email. [336218] [James Monroe] [Entered: 05/17/2016 06:04 PM] (3) |
| May 16, 2016 | 4 | Entry of appearance for Rachel K. Hunnicutt as of counsel for Appellees Torrent Pharma Inc. and Torrent Pharmaceuticals Limited. Service: 05/16/2016 by email. [335284] [Rachel Hunnicutt] [Entered: 05/16/2016 12:44 PM] (2) |
| May 16, 2016 | 5 | Entry of appearance for Lawrence M. Sung as of counsel for Appellees Torrent Pharma Inc. and Torrent Pharmaceuticals Limited. Service: 05/16/2016 by email. [335313] [Lawrence Sung] [Entered: 05/16/2016 01:21 PM] (2) |
| May 16, 2016 | 6 | Entry of appearance for A. Neal Seth as principal counsel for Appellees Torrent Pharma Inc. and Torrent Pharmaceuticals Limited. Service: 05/16/2016 by email. [335316] [Neal Seth] [Entered: 05/16/2016 01:25 PM] (2) |
| May 16, 2016 | 7 | Certificate of Interest for the Appellees Torrent Pharma Inc. and Torrent Pharmaceuticals Limited. Service: 05/16/2016 by email. [335435] [Neal Seth] [Entered: 05/16/2016 03:25 PM] (2) |
| May 16, 2016 | 8 | Entry of appearance for Elizabeth J. Holland as principal counsel for Appellee Teva Pharmaceuticals USA, Inc.. Service: 05/16/2016 by email. [335459] [Elizabeth Holland] [Entered: 05/16/2016 03:37 PM] (2) |
| May 16, 2016 | 9 | Entry of appearance for William M. Jay as of counsel for Appellee Teva Pharmaceuticals USA, Inc.. Service: 05/16/2016 by email. [335465] [William Jay] [Entered: 05/16/2016 03:41 PM] (2) |
| May 16, 2016 | 10 | Entry of appearance for Keith A. Zullow as of counsel for Appellee Teva Pharmaceuticals USA, Inc.. Service: 05/16/2016 by email. [335469] [Keith Zullow] [Entered: 05/16/2016 03:43 PM] (2) |
| May 16, 2016 | 11 | Entry of appearance for Srikanth K. Reddy as of counsel for Appellee Teva Pharmaceuticals USA, Inc.. Service: 05/16/2016 by email. [335473] [Srikanth Reddy] [Entered: 05/16/2016 03:46 PM] (2) |
| May 16, 2016 | 12 | Certificate of Interest for the Appellee Teva Pharmaceuticals USA, Inc.. Service: 05/16/2016 by email. [335478] [Elizabeth Holland] [Entered: 05/16/2016 03:49 PM] (2) |
| May 16, 2016 | 13 | Docketing Statement for the Appellee Teva Pharmaceuticals USA, Inc.. Service: 05/16/2016 by email. [335483] [Elizabeth Holland] [Entered: 05/16/2016 03:51 PM] (3) |
| May 16, 2016 | 14 | Docketing Statement for the Appellees Torrent Pharma Inc. and Torrent Pharmaceuticals Limited. Service: 05/16/2016 by email. [335498] [Neal Seth] [Entered: 05/16/2016 04:00 PM] (3) |
| May 3, 2016 | 1 | Appeal docketed. Received: 05/02/2016. [331662]Appellant/Petitioner's brief is due 07/05/2016. [SJ] [Entered: 05/03/2016 01:29 PM] (42) |
| May 3, 2016 | 2 | Note to file: The following cases are associated:16-1962 (lead) with 16-1963, -1964, -1965, -1966, -1967, -1968, -1969, -1970, -1971, -1972, -1973, -1974, -1975, -1977, -1978. FURTHER ENTRIES WILL BE ADDED TO THE LEAD APPEAL ONLY. [331829] [16-1962, 16-1963, 16-1964, 16-1965, 16-1966, 16-1967, 16-1968, 16-1969, 16-1970, 16-1971, 16-1972, 16-1973, 16-1974, 16-1975, 16-1977, 16-1978] [SJ] [Entered: 05/03/2016 04:12 PM] (0) |
| May 3, 2016 | 3 | Official caption revised to add all parties from consolidated appeals. The official caption is reflected on the electronic docket under the listing of the parties and counsel. EOAs, COIs, and docketing statements due 05/17/2016. Service as of this date by Clerk of Court. [331847] [SJ] [Entered: 05/03/2016 04:44 PM] (0) |
